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vs. 0.056 respectively; p = 0.012). When the FP group was 
compared to the other ICS, the event rate was even higher 
(0.077 vs. 0.058, respectively; p < 0.001). COPD exacer-
bations were more frequent in patients taking ICS, with 
significantly greater rate in the FP group compared to that 
seen with other ICS (0.93 vs. 0.84 respectively; p = 0.013).
Conclusions ICS use was associated an increase in respir-
atory adverse event rates, but whether this was due to more 
severe illness at entry is unknown. In subgroup analysis, the 
excess of morbidity in the ICS group appeared to be mainly 
associated with those receiving FP at randomisation.
Keywords Fluticasone · Inhaled corticosteroids · 
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Introduction
Chronic obstructive pulmonary disease (COPD) is charac-
terised by poor and worsening lung function, and signifi-
cant patient and societal burdens [1]. Prevention and treat-
ment of exacerbations have been identified by the Global 
Initiative for Chronic Obstructive Lung Disease (GOLD) 
as a priority since they are associated with lung function 
decline. The recommendation of inhaled corticosteroid/
long-acting β2 agonist combinations (ICS/LABA) is based 
on evidence of a reduction in exacerbations in studies such 
as TORCH [2]. Re-analyses of studies such as the TORCH 
have cast doubt on whether the corticosteroid component 
of these combinations, is efficacious [3]. However, ICS and 
ICS/LABA combinations are commonly prescribed inap-
propriately early in the course of the disease where bron-
chodilator therapies (short acting bronchodilators, long-act-
ing muscarinic antagonists (LAMAs), LABAs) may have 
been more suitable [4, 5]. The recent results of the FLAME 
Abstract 
Rationale Unlike many other COPD studies, the 4-year 
UPLIFT trial permitted inhaled corticosteroid (ICS) use 
during run-in and treatment phases. This provided the 
opportunity to prospectively observe the continuing effects 
of ICS on respiratory events in closely observed COPD 
population.
Objectives We aimed to determine rate and number of 
episodes of pneumonia and exacerbations of COPD in 
patients entering the study on no ICS, fluticasone proprion-
ate (FP), and other ICS.
Methods The UPLIFT dataset was examined retrospec-
tively, and patients were divided into three groups based 
on their medications at entry: no ICS, FP and other ICS. 
Poisson regression was used to compare the frequency of 
respiratory adverse events.
Measurements and Main Results At entry, the groups 
were well matched apart from a higher FEV1% predicted 
(38 vs. 41%; ICS vs. no ICS, respectively) and prevalence 
of current smoking (26 vs. 36%; ICS vs. no ICS, respec-
tively). Incidence rates of pneumonia were significantly 
higher in patients taking ICS compared to no ICS (0.068 
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study call this strategy into further question [6]. Not only 
has the efficacy of ICS in COPD, especially mild-to-mod-
erate disease, remained open to question [4], but their use 
especially at the high doses recommended in COPD are 
now associated with significant adverse events such as 
pneumonia, cataracts, glaucoma, accelerated bone turnover 
and diabetes [7]. These are acknowledged in current man-
agement strategies and in guidelines to a varying extent, 
although there is no clear guidance on how the increased 
risk should inform decision-making by physicians [1, 8].
More recently, with respect to pneumonia, there has been 
debate as to whether all ICS carry a similar risk profile and 
whether these are dose-related. The majority of studies 
demonstrating increased pneumonia risk were performed 
with fluticasone propionate (FP) doses (500–1000 µg/day), 
including the 3-year TORCH and 2-year INSPIRE stud-
ies [2, 9–13]. Meta-analyses of randomised studies have 
reported an increased pneumonia risk of up to 70% with 
ICS use [14, 15]. However no or lower risk of pneumonia 
have been noted with budesonide compared to FP [16, 17]. 
Similar observations have been made from retrospective 
database analyses, and observational matched primary care 
medical records review [18, 19]. Of the studies of budeso-
nide and beclomethasone in COPD, only two have demon-
strated a significant increase in reported pneumonia [20, 
21].
Despite the growing evidence that FP-based therapies 
have higher rates of pneumonia criticisms have been raised 
including the lack of clear clinical information from data-
bases, poor patient-control matching, the retrospective 
nature of all analyses, and the mix of protocol designs com-
paring ICS/LABA versus their monotherapies and/or pla-
cebo. Indeed, the view of the European Medicines Agency, 
which adopted the Committee for Medicinal Products for 
Human Use, was that there was no difference in interclass 
respiratory adverse events between ICS [22]. In 2008, the 
then largest randomised controlled study of COPD patients, 
the UPLIFT study, was published [23]. An unusual feature 
of this 4-year study was that patients were maintained on 
existing non-cholinergic inhaled therapies whilst being 
randomised to tiotropium or matched placebo. We hypoth-
esised that a comparison of patients taking ICS at entry to 
the study would allow comparison of the rates of adverse 
respiratory events in patients taking FP compared to those 
on other ICS.
Methods
Clinical Study Design and Subjects
The study designs, recruitment criteria and procedures 
of the UPLIFT studies have been previously reported 
(UPLIFT clinical Trial registration: NCT00144339) [23]. 
Briefly, this was a multi-centre 4-year double-blind, paral-
lel-group study in COPD patients with moderate-to-severe 
airflow limitation randomised to placebo or tiotropium 
18 µg once daily. The two co-primary endpoints were the 
annual rate of decline in pre-bronchodilation forced expira-
tory volume in 1  s (FEV1) and the post-bronchodilator 
FEV1 after 30 days of randomisation to the completion of 
the study. Importantly, the subjects were permitted guide-
line-recommended therapies other than the study drug (tio-
tropium or placebo) and other than any alternative anti-cho-
linergic therapies. All subjects were ≥40 years of age, had 
a diagnosis of COPD, smoked for ≥10 pack years, were not 
on long-term oxygen therapy and had not had an exacer-
bation of COPD or respiratory infection within the last 4 
weeks of screening.
Exacerbations in the study were characterised as an 
increase in new onset of at least two or more symptoms of 
cough, sputum, sputum purulence, wheezing or dyspnoea 
for ≥3 days requiring additional treatment with antibiotics 
and/or systemic corticosteroids. Pneumonia was defined 
based on the investigator’s assessment of a respiratory 
adverse event.
Statistical Methods
Because of the greater certainty in obtaining baseline pre-
scribing data, it was decided that the analyses would be 
undertaken on an intention-to-treat basis. Baseline continu-
ous data are summarised by the median (25th /75th cen-
tiles); categorical data by n (%). Three different categories 
were analysed:
1. ICS (n = 3700) vs no ICS (n = 2292);
2. Within ICS, FP (n = 1981) versus other ICS (or non-
FP) (n = 1719);
3. Stratification of the latter three groups by presence/
absence of tiotropium, thus giving rise to six groups.
The relationship between the treatment groups (n = 2, 3 
or 6) and the frequency of events (pneumonia and COPD 
exacerbations) was analysed by Poisson regression. An 
assumption of Poisson data is that the mean number of 
events is equal to the variance. The question of overdis-
persion of Poisson data is addressed in the supplementary 
section of this study. Time-to-first event was plotted by 
Kaplan–Meier curves [24]; the Log-rank test was used to 
compare treatment groups. Statistical analysis of COPD 
exacerbations followed those for pneumonia except for inci-
dence rates which are presented per person-year because 
of the high frequency of exacerbations. Cox proportional 
hazards regression was used for COPD exacerbations from 
which hazard ratios (HRs) and 95% CIs estimated. The data 
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were rounded up to the nearest whole number. An arbi-
trary level of 5% statistical significance (two-tailed) was 
assumed. The Stata statistical computer package was used 
to analyse the data.
Results
Demographics and Other Baseline Characteristics
This is an analysis of a study which was not stratified at 
entry so some baseline between-group differences are 
to be expected. We anticipated that the ICS group would 
have greater morbidity than the non-ICS group. Baseline 
variables are given in Table 1. The average age was similar 
across groups with the proportion of men varying between 
72 and 76%, and the majority of patients were Caucasian. 
There were proportionately more current smokers in the 
no ICS group (36%) compared to the ICS group (26%). 
FEV1% predicted was 3% lower on average for patients on 
any ICS when compared to no ICS (38 vs. 41%; ICS vs. no 
ICS, respectively). Thus, there were proportionately more 
severe patients and fewer smokers in the ICS group com-
pared to those with no ICS.
Comparison of ICS Groups
When those patients taking ICS were divided between FP 
and other ICS groups, there were no significant differences 
in the baseline characteristics. There were 1981 patients in 
the FP group and 1719 in the other ICS group. Similarly, 
there were no significant differences when the groups were 
further subdivided into tiotropium or placebo pairs.
Pneumonia Events
There were 854 patients with at least one pneumonia event 
(with 1121 events in total) (Supplementary Table 1). The 
total person-years in study was 17,721. Table 2 also sum-
marises the numbers of pneumonia events in individual 
patients, i.e. 688 patients with one pneumonia event, 228 
with two pneumonia events, etc. Predicted incidence rates 
are plotted in Supplementary Fig. 1, and the incidence rate 
ratios (IRRs) are shown in Table 3.
Table 1  Baseline demographics
Calculations subject to rounding errors
Numbers are median (25/75th centiles continuous data), n (%) for categorical. Rounding errors
ICS Inhaled corticosteroids, yrs years, Pred predicted
Variable Fluticasone Other ICS No ICS
Placebo Tiotropium Placebo Tiotropium Placebo Tiotropium
(n = 987) (n = 994) (n = 873) (n = 846) (n = 1146) (n = 1146)
Age (years) 65 (59, 71) 66 (59, 71) 65 (59, 71) 65 (59, 71) 65 (58, 71) 64 (58, 70)
Age ≥70 297 (30%) 315 (32%) 280 (33%) 269 (31%) 352 (31%) 311 (27%)
Sex (men) 716 (73%) 714 (72%) 653 (77%) 652 (75%) 853 (74%) 885 (77%)
Race
 White 895 (91%) 912 (92%) 804 (92%) 769 (91%) 998 (87%) 1010 (88%)
 Black 19 (2%) 13 (1%) 4 (<1%) 50 (10%) 96 (8%) 99 (10%)
 Asian 48 (5%) 43 (4%) 41 (5%) 21 (3%) 22 (2%) 18 (2%)
Unknown 3 (<1%) 26(3%) 24 (3%) 21 (3%) 22 (2%) 18 (2%)
Smoker current 242 (25%) 247 (25%) 234 (28%) 214 (25%) 422 (37%) 413 (36%)
FEV1 (L) 1.02 (0.76, 1.33) 0.99 (0.76, 1.29) 1.01 (0.75, 1.35) 1.05 (0.79, 1.34) 1.1 (0.83, 1.39) 1.1 (0.83, 1.43)
FEV1PostBD 1.24 (0.94, 1.58) 1.22 (0.96, 1.57) 1.26 (0.94, 1.61) 1.3 (1.159) 1.36 (1.01, 1.65) 1.35 (1.05, 1.7)
FEV1% Pred 38 (29, 47) 38 (29, 47) 38 (29, 47) 39 (30, 48) 41 (32, 50) 40 (32, 51)
FEV1%predBD 36 (36, 56) 47 (37, 57) 47 (26, 57) 48 (37, 57) 50 (41, 59) 50 (40, 60)
FVC (L) 2.52 (2.02, 3.13) 2.5 (1.94, 3.07) 2.51 (2, 3.12) 2.59 (2.06, 3.15) 2.6 (2.03, 3.19) 2.62 (2.07, 3.15)
FVC% Pred 74 (62, 86) 73 (61, 86) 73 (60, 85) 74 (62, 86) 76 (64, 88) 75 (63, 88)
Severity I/II 189 (19%) 186 (19%) 169 (19%) 173 (20%) 285 (25%) 307 (27%)
 III 532 (54%) 539 (54%) 445 (51%) 443 (52%) 633 (54%) 592 (52%)
 IV 245 (25%) 244 (25%) 229 (26%) 204 (24%) 216 (19%) 220 (19%)
Unknown 21 (2%) 25 (3%) 30 (3%) 26 (3%) 18 (2%) 27 (2%)
284 Lung (2017) 195:281–288
1 3
Any ICS versus None
The distribution of pneumonia events by treatment group 
is given in Table  2a along with person-years exposure. 
The incidence rates of pneumonia was significantly higher 
in ICS patients compared with those with none (0.068 vs. 
0.056, respectively; p = 0.012) (Fig.  1a). A similar trend 
was observed in the time-to-first event.
FP Versus Other ICS versus None
The distribution of pneumonia events by treatment group 
is given in Table 2b. The incidence rates were highest for 
the FP patients (0.077); lowest was for the no ICS group 
(0.058). An overall pair-wise comparison found a sig-
nificant difference between FP (higher incidence) and the 
other ICS reference group (p < 0.001). An attenuated rate 
of pneumonia, irrespective of ICS, was mainly found in the 
tiotropium subgroup (Table 2c).
Time‑to‑1st Pneumonia Event
There was a significant difference between the time-to-first 
pneumonia event and treatment group with a shorter dura-
tion to first event in the FP group (p = 0.021) (Fig. 1b).
Table 2  Distribution of 
pneumonia events and incidence 
rates
ICS Inhaled corticosteroids, FP fluticasone propionate, tio tiotropium, plac placebo
Treatment Events Years in study Incidence rate Incident rate ratio (95% CI) p value
(A)
 No ICS 383 6885 0.056 Reference
 ICS 738 10,836 0.068 1.22 (1.08, 1.38) 0.012
(B)
 FP 437 5685 0.077 1.38 (1.20, 1.58) <0.001
 Other ICS 301 5151 0.058 1.05 0.52
 No ICS 383 6885 0.056 Reference
(C)
 FP/Plac 220 2720 0.081 1.45 (1.19, 1.77) <0.001
 FP/tio 217 2964 0.073 1.31 (1.08, 1.60) 0.006
 Other ICS/plac 153 2461 0.062 1.12 (0.90, 1.38) 0.29
 Other ICS/tio 148 2690 0.055 0.99 (0.79, 1.23) 0.94
 No ICS/plac 184 3317 0.055 Reference
 No ICS/tio 199 3567 0.056 1.00 (0.82, 1.22) 0.95
Table 3  Incidence of COPD 
exacerbations by treatment 
group
Calculations subject to rounding errors
Incidence rate ratios (IRRs) estimated from negative binomial regression
ICS Inhaled corticosteroids, FP fluticasone propionate, tio tiotropium, plac placebo
Treatment Exacerbations Incidence Incident rate ratio p value
(A)
 No ICS 4256 0.62 0.62 Reference
 ICS 9618 0.88 1.45 (1.36, 1.55) <0.001
(B)
 FP 5292 0.93 1.52 (1.41, 1.64) <0.001
 Other ICS 4326 0.84 1.38 (1.27, 1.43) <0.001
 No ICS 4256 0.62 Reference
(C)
 FP/Plac 2798 1.03 1.57 (1.41, 1.75) <0.001
 FP/tio 2494 0.84 1.27 (1.14, 1.41) <0.001
 Other ICS/plac 2178 0.88 1.37 (1.22, 1.68) <0.001
 Other ICS/tio 2148 0.80 1.20 (1.07, 1.33) 0.001
 No ICS/plac 2207 0.67 Reference
 No ICS/tio 2049 0.57 0.86 (0.77, 0.95) 0.005
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COPD Exacerbations
There were 4050 patients who had at least one COPD exac-
erbation (1942 had none). Supplementary Table 2 summa-
rises the number of subjects who had COPD exacerbations 
and their frequencies. The overall incidence of COPD exac-
erbations was 0.81 per person-years treatment.
ICS versus None
Table  3a presents exacerbation rate by treatment group. 
There were significant differences (more COPD exacerba-
tions) in the ICS groups compared to the group of patients 
not taking ICS (0.88 vs. 0.62; p < 0.001).
FP Versus Other ICS Versus None
There was a significant (>10%) higher incidence of COPD 
exacerbation in FP group compared to those on other ICS 
(p = 0.013) (Table 3b) (Supplementary Fig. 2).
Time‑to‑1st COPD Exacerbations
The hazard ratio was lowest in the non-ICS group and 
highest in the FP/placebo group (Table  4). There was 
no significant difference between the FP and the other 
ICS treatments. The Kaplan–Meier curves demonstrate 
the separation between the two ICS (FP and other ICS) 
groups and patients on no ICS which is apparent from 2 
years and persists to the end of study (Fig. 2).
Log-rank Chi-squared=2.97. df=1, p=0.08
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Fig. 1  a Time-to-1st pneumonia event: ICS versus no ICS. b Time-
to-first pneumonia event: Fluticasone versus other ICS vs no ICS
Table 4  Cox regression for time-to-1st COPD exacerbation
Calculations subject to rounding errors
ICS inhaled corticosteroids, HR hazard ratio, CI confidence interval
Treatment group HR (95% CI) p value
(A)
 Any ICS 1.37 (1.29, 1.47) 0.001
 None Reference
(B)
 Fluticasone 1.12 (1.04, 1.21) 0.003
 Other ICS Reference
 No ICS 0.77 (0.71, 0.83) <0.001
(C)
 Fluticasone
  Placebo 1.16 (1.04, 1.29) 0.005
  Tiotropium 0.96 (0.86, 1.07) 0.49
 Other ICS
  Placebo Reference
  Tiotropium 0.88 (0.78, 0.98) 0.031
 No ICS
  Placebo 0.77 (0.69, 0.86) <0.001
  Tiotropium 0.67 (0.60, 0.75) <0.001
Log-rank Chi-squared=9.9,df=2,p=0.006
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Fig. 2  Time-to-1st COPD exacerbation: Fluticasone versus other ICS 
versus no ICS
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Discussion
Our analysis of this large 4-year prospective randomised 
study has established that ICS use at baseline is associated 
with an increase in both pneumonia (>20%) and COPD 
exacerbations (45%) compared to those not on ICS. The 
ITT principle was used in these analyses because of the dif-
ficulties in ascertaining the use and adherence to ICS ther-
apy over a duration of the 4 years of study. ITT, although 
not ideal, was considered the safer analytic method in this 
secondary endpoint dataset. To support our assumptions, 
we conducted a number of sensitivity analyses without evi-
dence of any interactions (see supplementary methods). As 
anticipated, the two groups were not matched at baseline in 
severity, with a quarter of ICS subjects in GOLD stage IV 
vs 19% in the no ICS group. Similarly FEV1% predicted in 
ICS group was 38% compared to 41% in the no ICS group. 
Thus the uneven distribution of baseline characteristics 
make it impossible to determine whether the differences in 
outcome are due to the adverse effects of treatment or the 
greater disease severity in those receiving the more inten-
sive treatment.
In contrast, the 2 subgroups of patients receiving ICS 
that is, FP or other ICS, were very well matched in all the 
baseline characteristics. Thus, it is legitimate to compare 
the two treatment regimes on an intention-to-treat basis. In 
this study, we found a significant increase in the rate and 
number of cases of pneumonia and a significant increase in 
the number, but not the time-to-first event of COPD exac-
erbations. This suggests that any effect was disproportion-
ately exhibited in those with frequent exacerbations. As 
stated earlier, UPLIFT differs from other therapeutic trials 
in COPD in that concomitant medications were permitted 
throughout [23]. Thus, the increase of nearly a third in the 
episodes of pneumonia seen in our analysis poinst to an 
adverse effect of FP therapy rather than other factors such 
ICS withdrawal as seen in other studies. Indeed, when the 
frequency of pneumonia in the no ICS group is compared 
to the other ICS, rates are similar. Thus, almost all of the 
excess of pneumonia episodes due ICS treatment can be 
ascribed to FP (Table 2).
Episodes of COPD exacerbations were also increased in 
the FP group. However, the time-to-first exacerbation was 
initially similar across the 3 groups, before diverging with 
clear increase for both the ICS groups (Fig. 2). Given that 
there was less severe disease in the no ICS group, this sug-
gests that time-to-first event may be a less good marker of 
outcome than frequency of exacerbation. We suggest that 
ICS, and particularly FP as stated above, may adversely 
affect those prone to recurrent exacerbations of COPD: 
Contrary to many guideline recommendations [1, 25].
Our findings confirm the observations of several ran-
domised trials of varying durations and doses of FP. 
However, unlike the 2-year INSPIRE and 3-year TORCH 
studies where high HRs of pneumonia were reported [10, 
11], our analysis demonstrates a significant but more 
modest effect. It is also much lower than other shorter 
duration randomised trials and of studies with lower FP 
doses [12, 13]. We suggest that this may be due to the 
longer observation period of 4 years in UPLIFT. Retro-
spective database and case–control analyses of longer 
durations have also reported higher rates of pneumonia 
[18, 19].
Our observations are similar to the retrospective 
case–control PATHOS study which found lower rates of 
COPD exacerbations and pneumonia in patients treated 
with budesonide/formoterol compared to FP/salmeterol 
[19, 26]. In a study of dual bronchodilators (LAMA/LABA 
combination) versus FP/salmeterol, the latter also resulted 
in significant increases in pneumonia and COPD exacerba-
tions in moderate-to-severe patients [27]. The superiority 
of dual bronchodilation over ICS/LABA has also been con-
firmed in the recent FLAME study [6].
Fluticasone differs from other ICS, such as beclometh-
asone and budesonide, in the presence of a fluorine moi-
ety. This drags the electrons across the molecule altering 
not only potency but also lipid solubility [28, 29]. In vivo 
this is characterised by an alteration in the volume of dis-
tribution, fluticasone dwelling for longer in the lipid mem-
branes. The consequence of this is a slower clearance from 
the lungs and other tissues. This will clearly have effects 
on lung immunity and epithelial barrier function [30]; thus, 
dampening down inflammatory responses. Alternatively, 
potent steroids may increase the risk of potential aspiration 
events. That fluticasone particularly prone to these adverse 
effects is confirmed by recent reports of increased pneumo-
nia with fluticasone furoate in COPD [31, 32]. Our analy-
sis does not exonerate other ICS from adverse respiratory 
outcomes; it merely suggests that these are more prevalent 
with fluticasone. This is supported by a recent study sug-
gesting that withdrawal of ICS decreases the risk of pneu-
monia and that this is particularly marked with FP [33]. In 
ICS withdrawal study, WISDOM, a short-term increase in 
adverse respiratory events was observed on gradual ster-
oid withdrawal from triple inhaled therapy [34]. In con-
trast, in the FLAME study, abrupt withdrawal of ICS did 
not increase exacerbation rates [6]. Asthma COPD overlap 
syndrome (ACOS) [35] may explain some of the anomalies 
seen in these studies.
A clear observation from this analysis is that long-act-
ing bronchodilator therapy in the form of tiotropium ame-
liorates some of the adverse effects of ICS treatment with 
the incidence rates returning towards those patients taking 
other ICS. We suggest that the use of ICS without LAMA 
may expose the patient to additional risk of respiratory 
adverse events.
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We conducted the analyses on the classic basis of inten-
tion to treat despite this our observations have strengths and 
weaknesses. This large study population was observed over 
a 4-year period in patients with a range of airflow limita-
tion and COPD severity. Co-existing treatment with ICS 
was uninfluenced either at study entry or during the course 
of the study. This avoids a major source of bias. A down-
side of this analysis is that we have not corrected for with-
drawal or changing of ICS during the course of the study. 
In this regard, we are conducting the analysis on the basis 
of ‘intention to treat’. A further limitation of this study is 
the reliance on secondary endpoints which were less tightly 
defined. Thus, exacerbations of COPD were defined as an 
increase in new onset of at least or more symptoms for >3 
days which required additional treatment with antibiotics 
and/or corticosteroids. It is likely therefore that some cases 
of pneumonia were included in this loose definition. Pneu-
monia was only defined as an investigator-reported adverse 
event not necessarily requiring confirmation by chest X-ray. 
In contrast to several large database studies with similar 
findings, the prospective nature and rigid diagnostic criteria 
for entry into UPLIFT ensures that our analysis has been 
performed on a clearly defined COPD population.
Conclusion
In conclusion, our analyses have shown that the use of FP 
in patients with COPD is associated with a significant risk 
of pneumonia and increase in COPD exacerbations com-
pared to patients on other ICS or those not taking any ICS. 
Although our observations are a secondary analysis of the 
large UPLIFT study, the magnitude of this intra-class dif-
ference needs to be put into context when choosing optimal 
therapy for COPD patients. Our results add further weight 
to the body of evidence cautioning against the use of fluti-
casone in this disease.
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